{"id":"W4313416609","doi":"10.21037/jgo-22-86","title":"A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal of Gastrointestinal Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; Juravinski Cancer Centre; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"National Cancer Institute","keywords":"Medicine; Trametinib; MEK inhibitor; Progressive disease; KRAS; Internal medicine; Clinical endpoint; Adverse effect; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Clinical trial; Gastroenterology; Progression-free survival; Concomitant; Gemcitabine; Chemotherapy; Surgery; Kinase; MAPK/ERK pathway; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001065441,0.0001557749,0.001171924,0.0004263835,0.00009420711,0.000003170304,0.0001400155,0.00004180774,0.0002050862],"category_scores_gemma":[0.0008889025,0.0001183744,0.00009772169,0.0002926289,0.0003022206,0.0000788103,0.0001174048,0.0008307713,5.633018e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003504044,"about_ca_system_score_gemma":0.001161812,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001634333,"about_ca_topic_score_gemma":0.000006363624,"domain_scores_codex":[0.9976473,0.0003683064,0.0009132701,0.0001842406,0.0005533897,0.000333494],"domain_scores_gemma":[0.9979652,0.0005541522,0.0007805278,0.0001470652,0.0003273831,0.0002256982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.307734,0.01016506,0.6756603,0.00004633943,0.00009753899,0.001335301,0.0003985648,0.00001330712,0.0009797848,0.0000251205,0.000090522,0.003454115],"study_design_scores_gemma":[0.2529207,0.3678139,0.3689316,0.0001622358,0.0003167027,0.008586824,0.0008818477,0.0001070971,0.00001308611,0.00005310288,0.0001418556,0.00007104841],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977143,0.0001663782,0.00006511761,0.0008397413,0.00007960955,0.0006876595,0.00001110004,0.000004421337,0.0004316947],"genre_scores_gemma":[0.981662,0.00001671576,0.01802472,0.00008610023,0.00008941629,0.00002693128,0.000006329306,0.00001630896,0.00007141241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3576488,"threshold_uncertainty_score":0.4827166,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02136824873145324,"score_gpt":0.3344853763190478,"score_spread":0.3131171275875946,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}